JP2006512090A5 - - Google Patents

Download PDF

Info

Publication number
JP2006512090A5
JP2006512090A5 JP2005507928A JP2005507928A JP2006512090A5 JP 2006512090 A5 JP2006512090 A5 JP 2006512090A5 JP 2005507928 A JP2005507928 A JP 2005507928A JP 2005507928 A JP2005507928 A JP 2005507928A JP 2006512090 A5 JP2006512090 A5 JP 2006512090A5
Authority
JP
Japan
Prior art keywords
seq
amino acids
acid sequence
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005507928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512090A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/034348 external-priority patent/WO2005016233A2/en
Publication of JP2006512090A publication Critical patent/JP2006512090A/ja
Publication of JP2006512090A5 publication Critical patent/JP2006512090A5/ja
Pending legal-status Critical Current

Links

JP2005507928A 2002-10-31 2003-10-28 ボツリヌス神経毒b受容体およびその使用 Pending JP2006512090A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42295102P 2002-10-31 2002-10-31
US49812803P 2003-08-27 2003-08-27
PCT/US2003/034348 WO2005016233A2 (en) 2002-10-31 2003-10-28 Botulinum neurotoxin b receptors and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009229744A Division JP2010006833A (ja) 2002-10-31 2009-10-01 ボツリヌス神経毒b受容体およびその使用

Publications (2)

Publication Number Publication Date
JP2006512090A JP2006512090A (ja) 2006-04-13
JP2006512090A5 true JP2006512090A5 (cg-RX-API-DMAC7.html) 2006-06-01

Family

ID=34197667

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005507928A Pending JP2006512090A (ja) 2002-10-31 2003-10-28 ボツリヌス神経毒b受容体およびその使用
JP2009229744A Pending JP2010006833A (ja) 2002-10-31 2009-10-01 ボツリヌス神経毒b受容体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009229744A Pending JP2010006833A (ja) 2002-10-31 2009-10-01 ボツリヌス神経毒b受容体およびその使用

Country Status (10)

Country Link
US (2) US20040191887A1 (cg-RX-API-DMAC7.html)
EP (1) EP1578382B1 (cg-RX-API-DMAC7.html)
JP (2) JP2006512090A (cg-RX-API-DMAC7.html)
AT (1) ATE442161T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003304419A1 (cg-RX-API-DMAC7.html)
CA (1) CA2504532C (cg-RX-API-DMAC7.html)
DE (1) DE60329225D1 (cg-RX-API-DMAC7.html)
ES (1) ES2333319T3 (cg-RX-API-DMAC7.html)
IL (1) IL167943A (cg-RX-API-DMAC7.html)
WO (1) WO2005016233A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003304419A1 (en) * 2002-10-31 2005-03-07 Wisconsin Alumni Research Foundation Botulinum neurotoxin b receptors and use thereof
US7341843B2 (en) * 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US8748106B2 (en) * 2005-04-18 2014-06-10 Bal Ram Singh Methods of identifying a compound that increases or decreases the interaction of Hn-33 with synaptotagmin II
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
CN101932936B (zh) 2007-09-14 2016-04-27 拜奥麦迪逊公司 利用切割序列和间隔子的共振能量转移测定
US9303285B2 (en) 2012-01-04 2016-04-05 Biomadison, Inc. Methods and compounds for increasing sensitivity of botulinum assays
US11325954B2 (en) 2011-06-01 2022-05-10 Biomadison, Inc. Compositions and methods for stability testing of botulinum toxin
US12422428B2 (en) 2011-06-01 2025-09-23 Biomadison, Inc. Compositions and methods for cell-based assays
US10908146B2 (en) 2011-06-01 2021-02-02 Biomadison, Inc. Compositions and methods for improving sensitivity in cell based assays
US9274121B2 (en) 2011-06-01 2016-03-01 Biomadison, Inc. Non-FRET botulinum assay
EP3270162B2 (en) 2013-08-09 2023-08-16 BioMadison, Inc. Botulinum toxin assay with improved sensitivity
WO2023210585A1 (ja) * 2022-04-25 2023-11-02 株式会社Jiksak Bioengineering 標的化剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994995B1 (en) * 2001-03-16 2006-02-07 Lexicon Genetics Incorporated Human synaptotagmin and polynucleotides encoding the same
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
AU2003304419A1 (en) * 2002-10-31 2005-03-07 Wisconsin Alumni Research Foundation Botulinum neurotoxin b receptors and use thereof
EP2502930B1 (en) * 2003-12-19 2016-06-29 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
WO2008036060A2 (en) * 2005-04-05 2008-03-27 Allergan, Inc. Clostridial toxin activity assays
ES2426194T3 (es) * 2005-08-02 2013-10-21 Planet Biotechnology, Inc. Proteínas quiméricas del receptor de toxina mejoradas y proteínas quiméricas del receptor de toxina para el tratamiento y la prevención de anthrax
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
WO2013011055A1 (en) * 2011-07-19 2013-01-24 ETH Zürich Means and methods for determining clostridial neurotoxins

Similar Documents

Publication Publication Date Title
Matsumoto et al. The distribution of tenascin-X is distinct and often reciprocal to that of tenascin-C.
EP3802922B1 (en) Novel immune checkpoint inhibitors
Sheng et al. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity
Khachigian et al. Egr-1-induced endothelial gene expression: a common theme in vascular injury
Takahashi et al. Endothelin in the gastrointestinal tract: presence of endothelinlike immunoreactivity, endothelin-1 messenger RNA, endothelin receptors, and pharmacological effect
Vogrin et al. Evolutionary differences in the Vegf/Vegfr code reveal organotypic roles for the endothelial cell receptor Kdr in developmental lymphangiogenesis
JP2004512022A5 (cg-RX-API-DMAC7.html)
EP2577315B1 (en) Markers for renal disease
JP2006523440A (ja) 若年性ヘモクロマトーシス遺伝子(hfe2a)、その発現産物および使用法
JP2003501038A5 (cg-RX-API-DMAC7.html)
CA2370493A1 (en) Peptides and assays for the diagnosis of lyme disease and compositions useful for the prevention thereof
AU2013240301B2 (en) A novel interferon-lambda4 (IFNL4) protein, related nucleic acid molecules, and uses thereof
JP2004512824A5 (cg-RX-API-DMAC7.html)
JPS61502491A (ja) 組織型およびウロキナ−ゼ型プラスミノ−ゲン活性化因子の阻害物質に対する診断検定
JPH1099087A5 (cg-RX-API-DMAC7.html)
EP1208196B1 (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
JP2009513118A5 (cg-RX-API-DMAC7.html)
JP2006518582A5 (cg-RX-API-DMAC7.html)
KR102574799B1 (ko) 마약 중독 또는 금단증상 진단용 바이오마커 조성물 및 마약 중독 또는 금단증상 진단용 키트
JP2009297021A5 (cg-RX-API-DMAC7.html)
JP2006502738A5 (cg-RX-API-DMAC7.html)
EP1141292A1 (en) Monocyte-derived nucleic acids and related compositions and methods
US20060137029A1 (en) Novel G protein-coupled receptor encoding gene and diagnostic uses therefor
JP5709815B2 (ja) 脳型有機アニオントランスポーターとその遺伝子
Brydon et al. Investigation of the human Mel 1a melatonin receptor using antireceptor antibodies